SCHEDULE 14A INFORMATION


                 Proxy Statement Pursuant to Section 14(a)
                   of the Securities Exchange Act of 1934



Filed by the Registrant |X|
Filed by a Party other than the Registrant |_|
Check the appropriate box:
|_|      Preliminary Proxy Statement
|_|      Confidential, for Use of the Commission Only (as permitted by
         Rule 14a-6(e)(2))
|_|      Definitive Proxy Statement
|_|      Definitive Additional Materials
|X|      Soliciting Material Pursuant to Rule 14a-11(c) or 14a-12


                                E-Z-EM, Inc.
              (Name of Registrant as Specified in Its Charter)


                                E-Z-EM, Inc.
                 (Name of Person(s) Filing Proxy Statement,
                       if other than the Registrant)

Payment of Filing Fee (check the appropriate box):

|X|      No fee required.

|_|      Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and
         0-11.

         o    Title of each class of securities to which transaction
              applies:
         o    Aggregate number of securities to which transaction applies:
         o    Per unit price or other underlying value of transaction
              computed pursuant to Exchange Act Rule 0-11 (Set forth the
              amount on which the filing fee is calculated and state how it
              was determined):
         o    Proposed maximum aggregate value of transaction:
         o    Total fee paid:

|_|      Fee paid previously with preliminary materials.

|_|      Check box if any part of the fee is offset as provided by Exchange
         Act Rule 0-11(a)(2) and identify the filing for which the
         offsetting fee was paid previously. Identify the previous filing
         by registration statement number, or the Form or Schedule and the
         date of its filing.
         o    Amount previously paid:
         o    Form, Schedule or Registration Statement No.:
         o    Filing Party:
         o    Date Filed:







FOR IMMEDIATE RELEASE                      CONTACT:  Dennis J. Curtin
                                           Senior Vice President - Chief
                                                 Financial Officer
                                           Telephone: (516) 333-8230, Ext. 320
                                           Email: dcurtin@ezem.com


             E-Z-EM BOARD APPROVES PLAN TO COMBINE OUTSTANDING
           CLASS A AND B SHARES INTO SINGLE CLASS OF COMMON STOCK

WESTBURY, NEW YORK, JULY 25, 2002 - E-Z-EM, Inc. (AMEX: EZM.A/EZM.B)
("E-Z-EM" or the "Company") today announced that its Board of Directors
approved a previously announced plan to combine the Company's two currently
outstanding classes of common stock - Class A (AMEX: EZM.A) and Class B
(AMEX: EZM.B) - into a single class of common stock.

As provided in the recapitalization merger agreement executed today by
E-Z-EM, the proposed transaction will be effected by merging a newly formed
subsidiary into E-Z-EM, with E-Z-EM continuing as the surviving corporation
in the merger. As a result of this merger, each outstanding Class A share
and each outstanding Class B share would be converted into one share of a
newly created class of common stock of the Company. Following the
transaction, there would be no super-majority voting requirements
applicable to the Company's new class of common stock in the Company's
certificate of incorporation, each holder would have one vote per share and
all matters brought before the stockholders of the Company, other than the
removal of directors, would be determined by a majority vote. E-Z-EM
expects the proposed transaction to be tax-free to the Company and the
holders of the Company's Class A and Class B shares. The transaction is
subject to the requisite approval of the holders of 66% of the shares of
Class A common stock actually voted on the proposal and other customary
conditions. The Company expects to submit the proposed transaction to a
vote of its stockholders at the Company's Annual Meeting of Stockholders
currently scheduled for October 15, 2002.

The Stern and Meyers families, which in the aggregate own approximately
64.2% of the Class A voting stock, have agreed to vote their shares in
favor of the proposed transaction.

ABOUT E-Z-EM, INC.

E-Z-EM, the world's largest manufacturer of contrast agents for
gastrointestinal radiology, has developed the only CT injector on the
market that can help detect contrast extravasation, the new EmpowerCT(TM)
with patented EDA(TM) technology. The Company has also recently introduced
a complete tool kit for virtual colonoscopy (also referred to as CT
colonography, or CTC), an innovative technology that could lead to a
substantial increase in the number of patients being screened for
colorectal cancer. Virtual colonoscopy visualizes the gastrointestinal
tract using advanced CT imaging and 3D computer reconstruction of that
data. The Company's product line consists of the InnerviewGI(TM) 3D imaging
workstation; LoSo Prep(TM) and NutraPrep(TM) patient-friendly colon
preparation products and nutritional meal kits; a tagging agent trade-named
Tagitol(TM) to help practitioners distinguish pathology from colonic
residue; and the PROTOCO2L(TM) carbon dioxide colon insufflation system.
E-Z-EM's wholly owned subsidiary, AngioDynamics, manufactures a wide range
of products, including angiographic, vascular access, thrombolytic,
angioplasty, stents, as well as abdominal infection drainage products.
AngioDynamics' focus is on diagnostic and therapeutic products for
interventional radiology and other areas of minimally invasive surgery.
Enteric Products, Inc., another subsidiary, develops, manufactures and
markets tests for detection of the ulcer- and cancer-causing bacterium
Helicobacter pylori. For additional information, please contact Dennis J.
Curtin, Senior Vice President - Chief Financial Officer, at (516) 333-8230,
Ext. 320 (Email: dcurtin@ezem.com) or visit our corporate web site at
www.ezem.com.

                              *   *   *   *   *

The statements made in this document contain certain forward-looking
statements that involve a number of risks and uncertainties. Words such as
"expects", "intends", "anticipates", "plans", "believes", "seeks",
"estimates," or variations of such words and similar expressions, are
intended to identify such forward-looking statements. Investors are
cautioned that actual events or results may differ from the Company's
expectations. In addition to the matters described above, the ability of
the Company to develop its products, future actions by the FDA or other
regulatory agencies, results of pending or future clinical trials, overall
economic conditions, general market conditions, foreign currency exchange
rate fluctuations, the effects on pricing from Group Purchasing
Organizations, competition, including alternative procedures which continue
to replace traditional fluoroscopic procedures, as well as the risk factors
listed from time to time in the SEC filings of E-Z-EM, Inc., including but
not limited to its Form 10-Q for the quarter ended March 2, 2002, as well
as its Annual Report on Form 10-K for the year ended June 2, 2001, may
affect the actual results achieved by the Company. There are also a number
of uncertainties, risks, conditions and other factors which could prevent
the implementation of the above described transaction.

In connection with its upcoming annual meeting of stockholders and the
above described transaction, E-Z- EM, Inc. will be filing a proxy statement
and other materials with the Securities and Exchange Commission. SECURITY
HOLDERS ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security
holders may obtain a free copy of these materials when they become
available, as well as other materials filed with the Securities and
Exchange Commission concerning E-Z-EM, Inc., at the Securities and Exchange
Commission's website at http://www.sec.gov. In addition, these materials
and other documents may be obtained for free from E-Z-EM, Inc. by directing
a request to E-Z-EM, Inc. at 717 Main Street, Westbury, NY 11590; Attn:
Investor Relations.

E-Z-EM, Inc. and its directors and executive officers may be deemed to be
participants in the solicitation of proxies from the Company's stockholders
with respect to the annual meeting and the transaction described above.
These directors and executive officers include the following: Anthony A.
Lombardo, Howard S. Stern, David P. Meyers, Michael A. Davis, James L.
Katz, Paul S. Echenberg, Donald A. Meyer, Dennis J. Curtin, Joseph J.
Palma, Arthur L. Zimmet and Brad Schreck. Collectively, as of July 10,
2002, the directors and executive officers of E-Z-EM, Inc., listed above
may be deemed to beneficially own approximately 33.45% of the Company's
outstanding Class A common stock.